![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DR Sohn, K Kobayashi, K Chiba, KH Lee, SG Shin and T Ishizaki
Department of Pharmacology, College of Medicine, Gyeongsang National University, Chinju, Korea.
To explore the relationship between omeprazole disposition and genetically determined S-mephenytoin 4'-hydroxylation phenotype status, we examined the kinetic variables of omeprazole and its two primary metabolites in plasma (5-hydroxyomeprazole and omeprazole sulfone) and the excretion profile of its principal metabolite in urine (5- hydroxyomeprazole) in eight extensive (EMs) and eight poor metabolizers (PMs) recruited from a Korean population. Each subject received a p.o. dose of 20 mg of omeprazole as an enteric-coated formulation, and blood and urine samples were collected up to 24 hr postdose. Omeprazole and its metabolites were measured by high-performance liquid chromatography with ultraviolet detection. The mean omeprazole area under the concentration-time curve (AUC), elimination half-life (T1/2) and apparent p.o. clearance were significantly (P less than .001) greater, longer and lower, respectively, in PMs than in EMs. The mean peak concentration and AUC of 5-hydroxyomeprazole and AUC ratio of 5- hydroxyomeprazole to omeprazole were significantly (P less than .01 to .001) less in PMs than in EMs. The mean peak plasma concentration, AUC of omeprazole sulfone and ratio of omeprazole sulfone to omeprazole were greater (P less than .001) and T1/2 was longer (P less than .001) in PMs than in EMs. The mean cumulative urinary excretion of 5- hydroxyomeprazole up to 24 hr postdose was significantly (P less than .001) less in PMs than in EMs. In addition, the log10 4'- hydroxymephenytoin excreted in urine correlated significantly (P less than .01) with the apparent p.o. clearance of omeprazole and half-lives of omeprazole, 5-hydroxyomeprazole and omeprazole sulfone.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  Q. Ma and A. Y. H. Lu CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies Drug Metab. Dispos., July 1, 2007; 35(7): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, M.-J. Kim, J. S. Bertino Jr, A. N. Nafziger, and E. M. Sellers Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults. J. Clin. Pharmacol., March 1, 2006; 46(3): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tang, J. H. Lin, and A. Y. H. Lu METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION? Drug Metab. Dispos., May 1, 2005; 33(5): 603 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Q. P. Yin, B. Tomlinson, A. H. L. Chow, M. M. Y. Waye, and M. S. S. Chow Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability J. Clin. Pharmacol., June 1, 2004; 44(6): 582 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Ma, A. N. Nafziger, and J. S. Bertino Jr. Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers J. Clin. Pharmacol., May 1, 2004; 44(5): 447 - 456. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Sinues, A. Fanlo, M. L. Bernal, M. Val, and E. Mayayo Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans Human and Experimental Toxicology, March 1, 2004; 23(3): 107 - 113. [Abstract] [PDF]
|
|
|
|
|
|
D. F. Lehmann, J. J. Medicis, and P. D. Franklin Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer J. Clin. Pharmacol., December 1, 2003; 43(12): 1316 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Gonzalez, E. M. Romero T, A. A. Peregrina L, T. d. J. Chavez C, E. Escobar-Islas, F. Lozano K, and C. Hoyo-Vadillo CYP2C19- and CYP3A4-Dependent Omeprazole Metabolism in West Mexicans J. Clin. Pharmacol., November 1, 2003; 43(11): 1211 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosuge, Y. Jun, H. Watanabe, M. Kimura, M. Nishimoto, T. Ishizaki, and K. Ohashi Effects of CYP3A4 Inhibition by Diltiazem on Pharmacokinetics and Dynamics of Diazepam in Relation to CYP2C19 Genotype Status Drug Metab. Dispos., October 1, 2001; 29(10): 1284 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shu, L.-S. Wang, Z.-H. Xu, N. He, W.-M. Xiao, W. Wang, S.-L. Huang, and H.-H. Zhou 5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 844 - 851. [Abstract] [Full Text]
|
|
|
|
|
|
J.-W. Ko, N. Sukhova, D. Thacker, P. Chen, and D. A. Flockhart Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms Drug Metab. Dispos., July 1, 1997; 25(7): 853 - 862. [Abstract] [Full Text]
|
|
|
|
|
|
C. Funck-Brentano, L. Becquemont, A. Leneveu, A. Roux, P. Jaillon, and P. Beaune Inhibition by Omeprazole of Proguanil Metabolism: Mechanism of the Interaction In Vitro and Prediction of In Vivo Results from the In Vitro Experiments J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 730 - 738. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
